CARsgen Therapeutics (2171 HK)

CARsgen Therapeutics is a clinical-stage biopharmaceutical company focused on discovering, researching, and developing innovative CAR T-cell therapies. The company's pipeline includes therapies for hematological malignancies, solid tumors, and autoimmune diseases, such as CT053 for multiple myeloma. It is headquartered in Shanghai, China, and was founded in 2014.